EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer

Luca Cantini, Dario Trapani, Lorenzo Guidi, Luca Boscolo Bielo, Roberta Scafetta, Marcin Koziej, Laura Vidal, Kamal S Saini, Giuseppe Curigliano

Cancer Treatment Reviews · 2024-02 · 123 · 102669

DOI: 10.1016/j.ctrv.2023.102669 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-02. Verfasst von Luca Cantini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fortrea Inc., Durham, NC, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyTriple Negative Breast NeoplasmsFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantMastectomy, SegmentalPatient SelectionErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Breast cancerGenomic signaturesHormone receptorNeoadjuvant chemotherapyNeoadjuvant endocrine therapy

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Fortrea Inc., Durham, NC, USA.
  • Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy; Division of New Drugs and Early Drug Development, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy; Division of New Drugs and Early Drug Development, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of medical…
  • Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy; Division of New Drugs and Early Drug Development, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy. Electronic address: gi…

Zitieren

APA

Cantini, L., Trapani, D., Guidi, L., Boscolo Bielo, L., Scafetta, R., Koziej, M., Vidal, L., Saini, K. S., & Curigliano, G. (2024). Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. Cancer Treatment Reviews, 123, 102669. https://doi.org/10.1016/j.ctrv.2023.102669

Vancouver

Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, et al. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. Cancer Treatment Reviews. 2024;123:102669. doi:10.1016/j.ctrv.2023.102669

BibTeX
@article{Cantini2024,
  author = {Cantini, Luca and Trapani, Dario and Guidi, Lorenzo and Boscolo Bielo, Luca and Scafetta, Roberta and Koziej, Marcin and Vidal, Laura and Saini, Kamal S and Curigliano, Giuseppe},
  title = {Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer},
  journal = {Cancer Treatment Reviews},
  year = {2024},
  volume = {123},
  pages = {102669},
  doi = {10.1016/j.ctrv.2023.102669}
}
Kostenlos starten →